Editas, SR-TIGET Collaborate
News Jul 29, 2016
Editas Medicine, Inc. and San Raffaele Telethon Institute for Gene Therapy (SR-TIGET) have entered into a scientific collaboration to research and develop genome edited hematopoietic stem cell (HSC) and T cell therapies. The scientific work at SR-TIGET in Milan, Italy will be led by Luigi Naldini, M.D., Ph.D., SR-TIGET Director, and a world-renowned expert in lentiviral gene therapy and hematology.
“Dr. Naldini and SR-TIGET are world leaders in gene therapy. They have pioneered many important scientific advancements working with cells of the immune system and have extensive expertise in translating that work into cell-based therapies,” said Katrine Bosley, CEO, Editas Medicine. “We believe there will be great synergy across our scientific teams through this collaboration.”
“My team and I believe genome editing is a promising answer to advance medicines to treat technically challenging diseases,” said Dr. Naldini. “We at San Raffaele Telethon Institute for Gene Therapy have worked for years to develop targeted integration of therapeutic genes into T cells and HSCs, and the collaboration with Editas Medicine represents an important opportunity to develop more effective and safe therapies for patients in the years ahead.”
The goal of the three-year research collaboration includes the development of gene correction strategies for the treatment of rare diseases, including two specified indications in the blood and bone marrow. This collaboration is part of Editas Medicine’s overall HSC and T cell editing product development strategy for challenging disease areas.
A human pluripotent stem cell line has been engineered which contains two ‘suicide genes’ that induce cell death in all but the desired insulin-producing cells. This double fail-safe approach opens the door to creating safe cell-replacement therapies for people living with type 1 diabetes.READ MORE
Researchers have shown that a single systemic treatment using CRISPR genome editing technology can safely and stably correct a genetic disease -- Duchenne muscular dystrophy (DMD) -- for more than a year in mice, despite observed immune responses and alternative gene editing outcomes.READ MORE